Zealand Pharma's restructuring plan has led to dismissals in Denmark
Last week’s announcement that Zealand Pharma was planning to scale down its operations in the US by 90 percent has had a wider impact than first assumed – CEO Adam Steensberg now tells MedWatch that Danish staffing has also been reduced.
by christopher due karlsson, translated by daniel pedersen
More than just Zealand Pharma’s employees in the US are bearing the brunt of the company’s streamlining plans. Danish staffing has also suffered a blow, says the newly appointed CEO, Adam Steensberg, to MedWatch.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma appoints head of R&D as CEO
For subscribers
Zealand Pharma reports higher costs in 2021
For subscribers
.jpg&w=384&q=75)
